Drugs / Adenovirus-specific CTL
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00590083 | Jul 2003 → Jan 2011 | adenoviridae infectious disease | Baylor College of Medicine | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Adenovirus-specific CTL | “One infusion of Adenovirus-specific CTL given to patients at risk for Adenoviral disease after matched or mismatched unrelated or matched or mismatched related donor stem cell...” NCT00590083 ↗ |
| Action | Deplete | “These cells can then stimulate the T lymphocytes and train them to kill cells infected with Ad.” NCT00590083 ↗ |
| Modality | Cell therapy | “infusions of single cytotoxic T lymphocyte (CTL) lines” PMID 19700662 ↗ Aug 2009 |
| Route | Intravenous | “Adenovirus specific T cells will be given by intravenous injection from day 30 post transplant.” NCT00590083 ↗ |